The future of drug development will rely on artificial intelligence, because biology is too complex for humans to understand
Our AI platform rapidly directs us to the best drug candidates. It knows biology, from disease biomarkers all the way down to the level of DNA, RNA and the molecular machinery of the cell. Everyone at Deep Genomics uses the platform to do their work, and everyone participates in improving the platform. That includes our geneticists, biologists, chemists, toxicologists, clinicians and drug developers. Now, we’re creating and clinically evaluating new oligonucleotide therapies, designed up front to be effective and safe.
Smart drug design is about predicting outcomes up front. That's what our AI platform does best, and Saturn is the proof
In Project Saturn, we're using our platform to evaluate over 69 billion molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended. Think of it as a toolkit for controlling cell biology along crucial pathways, rapidly unlocking therapies with greater potential.
Learn about the latest developments at Deep Genomics